Big pharma chair Michel Demaré points to proxy advisors as cause of block on higher pay while more FTSE 100 companies plan boost to packages.

But investment giant BlackRock’s chief executive said its focus on long-term investment and corporate governance would continue.

The FRC has commissioned a review to investigate how ESG ratings agencies and proxy advisers affect investment decisions.